Conference Coverage

How Early Should MS Treatment Begin?


 

References

“Can we select patients that will benefit from early treatment?” asked Prof. Fredrikson. “This is still an ongoing area, but in our practical everyday life, there is not enough evidence on these markers to select individual patients.”

Linda Peckel

Pages

Recommended Reading

FDA panel has mixed votes on alemtuzumab for multiple sclerosis
MDedge Neurology
Fine-Tuning the Ketogenic Diet May Benefit Children With Epilepsy—And Other News From the Child Neurology Society Meeting
MDedge Neurology
What Is the Future of Disease-Modifying Therapies for MS?
MDedge Neurology
New and Noteworthy Information—December 2013
MDedge Neurology
Teriflunomide Is Safe and Effective for Patients With CIS—Main Results From the TOPIC Study
MDedge Neurology
Repetitive TMS May Reduce Depression and Fatigue in Patients With MS
MDedge Neurology
Risk Stratification May Mitigate Adverse Events Associated With Newer MS Drugs
MDedge Neurology
Conference News Update—Society for Neuroscience
MDedge Neurology
Remyelination May Continue Despite Age in Patients With MS
MDedge Neurology
New and Noteworthy Information—January 2014
MDedge Neurology